Semaglutide/Tirzepatide Intermediates
Type 2 Diabetes/Obesity
Commercial/PlatformSupplied
Key Facts
About Sinopeg
A leading manufacturer of PEG derivatives and lipid excipients for advanced drug delivery systems, including mRNA vaccines and long-acting biologics.
View full company profileTherapeutic Areas
Other Type 2 Diabetes/Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilars (e.g., Semaglutide) | Phenotypeca | Commercial |
| HS-10511 | Hansoh Pharma | Phase I |
| IBI-362 | Innovent Biologics | Phase 3 |